



**Asia-Pacific
Economic Cooperation**

**APEC Life Sciences Innovation Forum
Enhancing Innovative Healthcare Financing in Pursuit of
Strong and Resilient Health Systems:
Financing Solutions for Durable Cures**

October 28, 2021

8:00 am EDT / 2:00 pm CEST / 7:00 pm ICT/WIB

8:00 pm HKT/SGT/CST/PHST / 9:00 pm JST/KST

Meeting Agenda	
8 min	<p><u>Opening Remarks and Welcome</u></p> <p>The moderator will briefly introduce the speakers and outline the objectives for the webinar.</p> <p>Moderator: Eric Obscherning, Private Sector Advisor to the APEC Life Sciences Innovation Forum</p>
10 min	<p><u>NEW Drug Development ParadIGmS (NEWDIGS)</u></p> <p>The Massachusetts Institute of Technology’s NEW Drug Development ParadIGmS (NEWDIGS) program is focused on enhancing the capacity of the global biomedical innovation system to reliably and sustainably deliver new, better, affordable therapeutics to the right patients faster. This session will focus on creating precision financing solutions and performance-based annuities to address financial challenges to therapeutics.</p> <p>Speaker: Mark Trusheim, Strategic Director & Visiting Scientist, Sloan School of Management, Massachusetts Institute of Technology</p>
10 min	<p><u>Chile’s Ricarte Soto Fund</u></p> <p>The purpose of the Financial Protection System for High Cost Diagnoses and Treatments, also known as the 'Ricarte Soto Law (RSL)', is to provide coverage for certain high-cost health technologies to all beneficiaries of the healthcare systems in Chile. This session will discuss how the Ricarte Soto Fund is being used to increase access to innovative medicines in Chile.</p>

	<p>Speaker: Dino Sepulveda, Head of Department of HTA and Evidence-Based Medicine, Ministry of Health, Chile; Executive Secretary, Ministerial Advisory Commission on Rare Diseases</p>
10 min	<p><u>Italy's Innovative Drugs Fund for Cancer and other Innovative Therapies</u></p> <p>In April 2017, two separate Innovative Drug Funds (for Innovative Oncology Drugs and for other Innovative Therapies respectively, € 500 Million each) were introduced by the Italian Ministry of Health to accelerate access to innovative therapies. Concurrently, a new algorithm was released under which the Italian Medicines Agency (AIFA) assesses the level of innovation provided by new therapies and their eligibility to be funded through this mechanism. In July 2021, the two Funds were unified (€1 Billion Fund for Innovative Drugs) and other measures are now being discussed at Government level.</p> <p>This session will cover how this Fund was created, how it is sustained, its impact on access to innovation and its role in the broader health financing context in Italy.</p> <p>Speaker: Goffredo Freddi, Executive Director, Policy & Communications at MSD Italy</p>
15 min	<p><u>Question and Answer Session</u></p> <p>Participants will be invited to submit questions using the chat function during the webinar. A moderated discussion will follow.</p>
7 min	<p><u>Summary and Next Steps</u></p> <p>A summary of the webinar's main points and recommendations as well as an overview of next steps and future webinars will be provided.</p>